Off-label use of anti-IL-1 drugs in rheumatic diseases
Silvia Stefania, Ripalta Colìa, Cinzia Rotondo, Addolorata Corrado, Francesco Paolo Cantatore
Abstract
Interleukin-1 (IL-1) plays a key role in the pathogenesis of different rheumatic diseases. There are now several agents available on the market capable of blocking IL-1. The proven effectiveness and excellent safety of these drugs makes them a possible therapeutic option in the treatment of IL-1 driven diseases, when previous therapies are contraindicated or ineffective. This article discusses the European wide off-label use of these drugs for the treatment of rheumatic diseases.
Topics & Concepts
MedicineBiological drugsPathogenesisRheumatoid arthritisIntensive care medicinePharmacologyImmunologyPharmaceutical studies and practicesImmunodeficiency and Autoimmune DisordersAsthma and respiratory diseases